Göttinger Graduiertenschule für Neurowissenschaften, Biophysik und Molekulare Biowissenschaften

Reichardt, Holger, Prof. Dr.

Professor of Experimental Immunology


  • 1989-1994: Studies in Biochemistry at the Universities of Tübingen, Munich and Fribourg/Switzerland
  • 1994-1997: PhD thesis at the German Cancer Research Center and the University of Heidelberg
  • 1997-2001: Junior group leader with Günther Schütz, German Cancer Research Center Heidelberg
  • 2001-2002: Independent group leader, Institute for Virology and Immunobiology, University of Würzburg
  • 2002-2006: Professor of Molecular Immunology, University of Würzburg
  • since 2007: Professor of Experimental Immunology, University of Göttingen



Major Research Interests

Inflammatory diseases such as Multiple Sclerosis, Type I Diabetes mellitus, Asthma and Graft-versus-Host-Disease are major health problems in the western world, often require lifetime medical treatment and may result in permanent disability and early death. Generally, therapy is often unsatisfactory and accompanied by side effects. Therefore our work aims at better understanding the mechanisms underlying traditional and new treatment regimens for chronic inflammatory diseases. First and foremost our approaches concern the mode of action of glucocorticoids, which are still the mainstay of many therapies employed in the clinic. To accomplish our goal, we primarily focus on T lymphocytes and myeloid cells and use a plethora of molecular and immunological techniques, different cell culture systems and a variety of animal models. Special expertise of our group also include the use of retroviral and lentiviral vectors for RNA interference and the generation of transgenic and knockdown mice and rats. Since glucocorticoid therapy is accompanied by metabolic side effects, some approaches in the lab also deal with the impact of anti-inflammatory therapies on muscle, liver, bone and the gastrointestinal tract. All our projects are integrated in a dense network of cooperation involving colleagues from allover the world.



Homepage Department/Research Group
http://www.immunologie.uni-goettingen.de/Reichardt/?



Selected Recent Publications


  • Tischner, D., Theiss, J., Karabinskaya, A., van den Brandt, J., Reichardt, S.D., Karow, U., Herold, M.J., Lühder, F., Utermöhlen, O., and Reichardt H.M. (2011). Acid Sphingomyelinase is required for protection of effector memory T cells against glucocorticoid-induced cell death. Journal of Immunology 187, 4509-4516.
  • van den Brandt, J., Fischer, H.J., Walter, L., Hünig, Th., Klöting, I., and Reichardt, H.M. (2010). Type 1 diabetes in BioBreeding rats is critically linked to an imbalance between Th17 and regulatory T cells and an altered TCR repertoire. Journal of Immunology 185, 2285-2294.
  • Rauch, A., Seitz, S., Baschant, U., Schilling, A.F., Illing, A., Stride, B., Kirilov, M., Mandic, V., Takacz, A., Schmidt-Ullrich, R., Ostermay, S., Schinke, T., Spanbroek, R., Zaiss, M.M., Angel, P.E., Lerner, U.H., David, J.P., Reichardt, H.M., Amling, M., and Schütz, G., and Tuckermann, J.P. (2010). Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metabolism 11, 517-531.
  • Wüst, S., Tischner, D., John, M., Tuckermann, J.P., Menzfeld, C., Hanisch, U.K., van den Brandt, J., Lühder, F., and Reichardt, H.M. (2009). Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of Multiple Sclerosis. PLoS One 4(12), e8202.
  • Tischner, D., van den Brandt, J., Weishaupt, A., Lühder, F., Herold, M., and Reichardt, H.M. (2009). Stable silencing of the glucocorticoid receptor in myelin-specific T effector cells by retroviral delivery of shRNAs: insight into neuroinflammatory disease. European Journal of Immunology 39, 2361-2370.
  • Herold, M.J., van den Brandt, J., Seibler, J., and Reichardt, H.M. (2008). Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats. Proceedings of the National Academy of Sciences USA 105, 18507-18512.
  • Wüst, S., van den Brandt, J., Tischner, D., Kleiman, A., Tuckermann, J.P., Gold, R., Lühder, F., and Reichardt, H.M. (2008). Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. Journal of Immunology 180, 8434-8443.
  • Müller, N., van den Brandt, J., Odoardi, F., Tischner, D., Herath, J., Flügel, A., and Reichardt, H.M. (2008). A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats. Journal of Clinical Investigation 118, 1405-1416.
  • Tuckermann, J.P., Kleiman, A., Moriggl, R., Spanbroek, R., Neumann, A., Illing, A., Clausen, B.E., Stride, B., Förster, I., Habenicht, A.J., Reichardt, H.M., Tronche, F., Schmid, W., and Schütz, G. (2007). Macrophages and Neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. Journal of Clinical Investigation 117, 1381-1390.
  • Tischner, D., Weishaupt, A., van den Brandt, J., Müller, N., Beyersdorf, N., Ip, C.W., Toyka, K.V., Hünig, T., Gold, R., Kerkau, T., and Reichardt, H.M. (2006). Polyclonal expansion of regulatory T cells interferes with effector cell migration in a model of Multiple Sclerosis. Brain 129, 2635-2647.